FDA approves new efficacy supplement for Novartis's Fabhalta
Novartis received priority-review approval for a seventh supplement to Fabhalta's original new drug application, expanding the drug's approved use.
The U.S. Food and Drug Administration approved a supplemental new drug application for Fabhalta (iptacopan hydrochloride), made by Novartis, according to FDA records. The submission was classified as an efficacy supplement, was reviewed under priority review, and was labeled submission number 7 for application NDA218276.1
The submission status is marked as approved, with a status date of July 16, 2026, according to the FDA database. The approval letter is dated July 20, 2026, and an updated product label along with a medication guide were issued on July 21, 2026.1
Fabhalta is formulated as an oral capsule. The product contains iptacopan hydrochloride, listed at a strength equivalent to 200 milligrams of the base compound.1
The FDA records provided do not specify the exact new indication, clinical trial data, or endpoint results supporting this seventh supplemental approval. Readers seeking those clinical details should consult the full approval letter and label documents once available, as the underlying database entry lists only administrative and regulatory information rather than efficacy findings.
No additional milestones or next steps beyond the approval itself are indicated in the available records.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.